Confirmation of results

Tissue Regenix Group PLC

21 August 2024

 

 Tissue Regenix Group plc

('Tissue Regenix' or 'the Group')

Confirmation of results

Investor presentation

Tissue Regenix (AIM: TRX), the regenerative medical devices company, confirms that the Group's interim results for the six months ended 30 June will be announced on Tuesday 10 September 2024.

Investor Briefing

Daniel Lee, Chief Executive Officer, and David Cocke, Chief Financial Officer, will host a live online presentation relating to the interim results via the Investor Meet Company platform at 4.30pm on Tuesday 10 September 2024. The presentation is open to all existing and potential shareholders.

Investors can sign up to Investor Meet Company for free and register for the presentation here:  

https://www.investormeetcompany.com/tissue-regenix-group-plc/register-investor

Investors who already follow Tissue Regenix on the Investor Meet Company platform will be de facto invited.

For more information:

Tissue Regenix Group plc	www.tissueregenix.com
Daniel Lee, Chief Executive Officer David Cocke, Chief Financial Officer	via Walbrook PR
Cavendish Capital Markets Limited (Nominated Adviser and Broker)
Emily Watts/Geoff Nash/ Edward Whiley - Corporate Finance
Nigel Birks/Harriet Ward - ECM
Walbrook PR (Financial PR and IR)	Tel: [phone]
Charlotte Edgar / Alice Woodings	[e-mail]

About Tissue Regenix (www.tissueregenix.com)

Tissue Regenix is a leading medical device company in regenerative medicine. The Company's patented decellularisation technology (dCELL®) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold not rejected by the patient's body that can be used to repair diseased or damaged body structures. Current applications address many crucial clinical needs in sports medicine, foot and ankle injuries and wound care.

 

END